A successfully novel ICD implantation and medical treatment in a child with LQT syndrome and self-limiting ventricular fibrillation

Fabrizio Drago, Giovanni Fazio, Massimo Stefano Silvetti, Gianluca Oricchio, Guido Michelon

Research output: Contribution to journalArticlepeer-review

Abstract

Beta-blocker is the first line drug therapy for congenital long QT syndrome. However, in some children this drug is ineffective. In a non-responder patient, Shimizu et al. used Mexiletine to suppress the ventricular arrhythmias, obtaining a good result. In the high risk patient, the ICD is necessary. However the implantation of a device in small children can have technical problems. We report a case of a child affected by long QT syndrome with recurrent episodes of syncope due to self-limiting torsade de point/ventricular fibrillation, successfully treated by an association of mexiletin and propanolol, and in whom an ICD was implanted with a new subcutaneous approach.

Original languageEnglish
JournalInternational Journal of Cardiology
Volume118
Issue number3
DOIs
Publication statusPublished - Jun 12 2007

Keywords

  • Beta-blockers
  • Congenital long QT syndrome
  • Flecainide
  • ICD

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'A successfully novel ICD implantation and medical treatment in a child with LQT syndrome and self-limiting ventricular fibrillation'. Together they form a unique fingerprint.

Cite this